Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aptose Bioscns (APTO)

Aptose Bioscns (APTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,661
  • Shares Outstanding, K 2,141
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,430 K
  • EBIT $ -36 M
  • EBITDA $ -36 M
  • 60-Month Beta 1.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -89.18
  • Most Recent Earnings $-11.11 on 11/08/24
  • Next Earnings Date 05/13/25
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -10.51
  • Number of Estimates 1
  • High Estimate -10.51
  • Low Estimate -10.51
  • Prior Year -43.24
  • Growth Rate Est. (year over year) +75.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3500 +26.67%
on 04/01/25
3.9799 -57.03%
on 03/18/25
-1.4800 (-46.39%)
since 02/28/25
3-Month
1.3500 +26.67%
on 04/01/25
7.7610 -77.97%
on 02/12/25
-5.0490 (-74.70%)
since 12/31/24
52-Week
1.3500 +26.67%
on 04/01/25
50.1000 -96.59%
on 04/02/24
-46.2900 (-96.44%)
since 04/01/24

Most Recent Stories

More News
Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial

APTO : 1.7100 (-45.71%)
APS.TO : 1.90 (+1.06%)
Aptose Announces Auditor Not Standing for Re-Appointment

APTO : 1.7100 (-45.71%)
APS.TO : 1.90 (+1.06%)
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

APTO : 1.7100 (-45.71%)
APS.TO : 1.90 (+1.06%)
Aptose Common Shares to Delist from Nasdaq as of April 2, 2025

APTO : 1.7100 (-45.71%)
APS.TO : 1.90 (+1.06%)
Aptose Reports Year End 2024 Results and Corporate Highlights

APTO : 1.7100 (-45.71%)
APS.TO : 1.90 (+1.06%)
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

APTO : 1.7100 (-45.71%)
APS.TO : 1.90 (+1.06%)
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort

APTO : 1.7100 (-45.71%)
APS.TO : 1.90 (+1.06%)
Aptose Announces Reverse Share Split

APTO : 1.7100 (-45.71%)
APS.TO : 1.90 (+1.06%)
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility

APTO : 1.7100 (-45.71%)
APS.TO : 1.90 (+1.06%)
Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial

APTO : 1.7100 (-45.71%)
APS.TO : 1.90 (+1.06%)

Business Summary

Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in...

See More

Key Turning Points

3rd Resistance Point 2.6567
2nd Resistance Point 2.3233
1st Resistance Point 2.0167
Last Price 1.7100
1st Support Level 1.3767
2nd Support Level 1.0433
3rd Support Level 0.7367

See More

52-Week High 50.1000
Fibonacci 61.8% 31.4775
Fibonacci 50% 25.7250
Fibonacci 38.2% 19.9725
Last Price 1.7100
52-Week Low 1.3500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar